New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray SystemCrystal Lake, Illinois, January 27, 2022 - Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multido.
Pharma major Glenmark Pharmaceuticals Limited on Friday said its fully owned Swiss subsidiary Glenmark Specialty S.A. has received the US Food and Drug Administration s (FDA) approval for nasal spray fixed dose prescription drug for seasonal .
Ryaltris™ has been approved and is marketed in Australia, the Czech Republic, Poland, Russia, South Africa, Ukraine, the United Kingdom, and Uzbekistan. Glenmark concluded the DCP regulatory procedure in Europe in April 2021, enabling approval in 17 countries across UK and EU.